Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherBEHAVIORAL PHARMACOLOGY

Pharmacological Activity and Safety Profile of P10358, a Novel, Orally Active Acetylcholinesterase Inhibitor for Alzheimer’s Disease

Craig P. Smith, Gina M. Bores, Wayne Petko, Mary Li, David E. Selk, Douglas K. Rush, Fernando Camacho, James T. Winslow, Rod Fishkin, Dana M. Cunningham, Karen M. Brooks, Joachim Roehr, Harold B. Hartman, Larry Davis and Hugo M. Vargas
Journal of Pharmacology and Experimental Therapeutics February 1997, 280 (2) 710-720;
Craig P. Smith
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gina M. Bores
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wayne Petko
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary Li
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David E. Selk
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Douglas K. Rush
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fernando Camacho
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James T. Winslow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rod Fishkin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dana M. Cunningham
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen M. Brooks
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joachim Roehr
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harold B. Hartman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Larry Davis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hugo M. Vargas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

1-[(3-Fluoro-4-pyridinyl)amino]-3-methyl-1(H)-indol-5-yl methyl carbamate (P10358) is a potent, reversible acetylcholinesterase inhibitor that produces central cholinergic stimulation after oral and parental administration in rats and mice. P10358 is a 2.5 times more potent acetylcholinesterase inhibitor than THA in vitro(IC50 = 0.10 ± 0.02 μM vs. IC50 = 0.25 ± 0.03 μM). It also inhibits butyrylcholinesterase activity as potently as THA (IC50 = 0.08 ± 0.05 μM vs. IC50 = 0.07 ± 0.01 μM). Ex vivo, P10358 (0.2 - 20 mg/kg, p.o.) produced dose-dependent inhibition of brain acetylcholinesterase activity. At 10 and 20 mg/kg, it produced profound and long-lasting hypothermia in mice. P10358 enhanced performance in rats in a step-down passive avoidance task (0.62 and 1.25 mg/kg) and in a social recognition paradigm (0.32, 0.64 and 1.25 mg/kg) in mice. It reversed scopolamine-induced deficits in the Morris Water maze in rats (1.25 and 2.5 mg/kg) and a higher dose elevated striatal homovanillic acid levels. These behavioral and biochemical effects are consistent with central cholinergic stimulation. Hemodynamic studies in the rat demonstrated a 16-fold separation between behaviorally active doses (1.25 mg/kg) and those that elevated arterial pressure (20 mg/kg). Lethality in rats occurred at an oral dose of 80 mg/kg, but not at lower doses. Chemically, P10358 is an N-aminoindole and may not have the hepatotoxic liability associated with aminoacridine structure of tacrine. P10358 had weak affinity (>10 μM) at a variety of aminergic and peptidergic receptors and uptake carriers. These properties suggest that P10358 may be a safe and promising symptomatic treatment for Alzheimer’s disease.

Footnotes

  • Send reprint requests to: Dr. Craig P. Smith, Hoechst Marion Roussel, Inc., Neuroscience TD, PO Box 6800, Routes 202–206, Bridgwater, NJ 08807-0800.

  • Abbreviations:
    AChE
    acetylcholinesterase
    AChEI
    acetylcholinesterase inhibitor
    AD
    Alzheimer’s disease
    BuChE
    butyrylcholinesterase
    DA
    dopamine
    DOPAC
    3,4-dihydroxyphenylacetic acid
    HEP
    heptylphysostigmine
    HVA
    homovanillic acid
    NE
    norepinephrine
    P10358
    1-[(3-Fluoro-4-pyridinyl)amino]-3-methyl-1(H)-indol-5-yl methyl carbamate
    SCOP
    scopolamine hydrobromide
    5-HT
    serotonin
    THA
    tacrine
    TRANYLCYP
    tranylcypromine
    MAP
    mean arterial pressure
    HR
    heart rate
    LSD
    least significant difference
    • Received May 6, 1996.
    • Accepted October 25, 1996.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 280, Issue 2
1 Feb 1997
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacological Activity and Safety Profile of P10358, a Novel, Orally Active Acetylcholinesterase Inhibitor for Alzheimer’s Disease
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherBEHAVIORAL PHARMACOLOGY

Pharmacological Activity and Safety Profile of P10358, a Novel, Orally Active Acetylcholinesterase Inhibitor for Alzheimer’s Disease

Craig P. Smith, Gina M. Bores, Wayne Petko, Mary Li, David E. Selk, Douglas K. Rush, Fernando Camacho, James T. Winslow, Rod Fishkin, Dana M. Cunningham, Karen M. Brooks, Joachim Roehr, Harold B. Hartman, Larry Davis and Hugo M. Vargas
Journal of Pharmacology and Experimental Therapeutics February 1, 1997, 280 (2) 710-720;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherBEHAVIORAL PHARMACOLOGY

Pharmacological Activity and Safety Profile of P10358, a Novel, Orally Active Acetylcholinesterase Inhibitor for Alzheimer’s Disease

Craig P. Smith, Gina M. Bores, Wayne Petko, Mary Li, David E. Selk, Douglas K. Rush, Fernando Camacho, James T. Winslow, Rod Fishkin, Dana M. Cunningham, Karen M. Brooks, Joachim Roehr, Harold B. Hartman, Larry Davis and Hugo M. Vargas
Journal of Pharmacology and Experimental Therapeutics February 1, 1997, 280 (2) 710-720;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgement
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Role of residues S426 and S430 in cannabinoid tolerance
  • DAT ligands on Cocaine-Food Choice in Monkeys
  • MDPV high-responders to evaluate candidate medications
Show more Behavioral Pharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics